Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1

American Journal of Hematology

Volumn 88, Issue 4, 2013, Pages 265-272

  Hawley, Teresa S ^a   Riz, Irene ^a   Yang, Wenjing ^a   Wakabayashi, Yoshiyuki ^b   Depalma, Louis ^a,c   Chang, Young Tae ^d,e   Peng, Weiqun ^a   Zhu, Jun ^b   Hawley, Robert G ^a,f  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e AGENCY FOR SCIENCE   (Singapore)

^f JINING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARFILZOMIB; FLUORESCENT DYE; MULTIDRUG RESISTANCE PROTEIN; VISMODEGIB;

ARTICLE; CANCER CELL; CELL SUBPOPULATION; CELL SURFACE; HEDGEHOG; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; UNITED STATES; UPREGULATION;

ANILIDES; ANTHRACENES; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SURVIVAL; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FLUORESCENT DYES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MORPHOLINES; MULTIPLE MYELOMA; NEOPLASTIC STEM CELLS; OLIGOPEPTIDES; P-GLYCOPROTEIN; PLASMA CELLS; PLURIPOTENT STEM CELLS; PYRIDINES;

EID: 84875583581     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23387     Document Type: Article

References (80)

1. Mahindra A, Laubach J, Raje N, et al. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol 2012;9:135-143.
2. Visvader JE, Lindeman GJ. Cancer stem cells: Current status and evolving complexities. Cell Stem Cell 2012;10:717-728.
3. Hamburger A, Salmon SE. Primary bioassay of human myeloma stem cells. J Clin Invest 1977;60:846-854.
4. Kastan MB, Schlaffer E, Russo JE, et al. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 1990;75:1947-1950.
5. Tang L, Bergevoet SM, Gilissen C, et al. Hematopoietic stem cells exhibit a specific ABC transporter gene expression profile clearly distinct from other stem cells. BMC Pharmacol 2010;10:12.
6. Moitra K, Lou H, Dean M. Multidrug efflux pumps and cancer stem cells: Insights into multidrug resistance and therapeutic development. Clin Pharmacol Ther 2011;89:491-502.
7. Alison MR, Lin WR, Lim SM, et al. Cancer stem cells: In the line of fire. Cancer Treat Rev 2012;38:589-598.
8. Hawley RG. The cancer stem cell conundrum in multiple myeloma. J Stem Cell Res Ther 2012;2:1000e110.
9. Goodell MA, Brose K, Paradis G, et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996;183:1797-1806.
10. Eaker SS, Hawley TS, Ramezani A, et al. Detection and enrichment of hematopoietic stem cells by side population phenotype. In: Hawley TS, Hawley RG, editors. Flow Cytometry Protocols, 2nd ed. Totowa, NJ: Humana Press, Inc.; 2004. pp 161-180.
11. Matsui W, Wang Q, Barber JP, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008;68:190-197.
12. Jakubikova J, Adamia S, Kost-Alimova M, et al. Lenalidomide targets clonogenic side population in multiple myeloma: Pathophysiologic and clinical implications. Blood 2011;117:4409-4419.
13. Im CN, Kang NY, Ha HH, et al. A fluorescent rosamine compound selectively stains pluripotent stem cells. Angew Chem Int Ed Engl 2010;49:7497-7500.
14. Kang NY, Yun SW, Ha HH, et al. Embryonic and induced pluripotent stem cell staining and sorting with the live-cell fluorescence imaging probe CDy1. Nat Protoc 2011;6:1044-1052.
15. Ben-Porath I, Thomson MW, Carey VJ, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008;40:499-507.
16. Kim J, Woo AJ, Chu J, et al. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 2010;143:313-324.
17. Chng WJ, Huang GF, Chung TH, et al. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 2011;25:1026-1035.
18. Namba M, Ohtsuki T, Mori M, et al. Establishment of five human myeloma cell lines. In Vitro Cell Dev Biol 1989;25:723-729.
19. Huang N, Kawano MM, Harada H, et al. Heterogeneous expression of a novel MPC-1 antigen on myeloma cells: Possible involvement of MPC-1 antigen in the adhesion of mature myeloma cells to bone marrow stromal cells. Blood 1993;82:3721-3729.
20. Dalton WS, Durie BG, Alberts DS, et al. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res 1986;46:5125-5130.
21. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell 2007;12:131-144.
22. Hawley RG, Ramezani A, Hawley TS. Hematopoietic stem cells. Methods Enzymol 2006;419:149-179.
23. Storms RW, Trujillo AP, Springer JB, et al. Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc Natl Acad Sci USA 1999;96:9118-9123.
24. Ni T, Corcoran DL, Rach EA, et al. A paired-end sequencing strategy to map the complex landscape of transcription initiation. Nat Methods 2010;7:521-527.
25. Langmead B, Trapnell C, Pop M, et al. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 2009;10:R25.
26. Lee S, Seo CH, Lim B, et al. Accurate quantification of transcriptome from RNA-Seq data by effective length normalization. Nucleic Acids Res 2011;39:e9.
27. Robinson MD, McCarthy DJ, Smyth GK. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010;26:139-140.
28. Riz I, Akimov SS, Eaker SS, et al. TLX1/HOX11-induced hematopoietic differentiation blockade. Oncogene 2007;26:4115-4123.
29. Riz I, Hawley TS, Johnston H, et al. Role of TLX1 in T-cell acute lymphoblastic leukaemia pathogenesis. Br J Haematol 2009;145:140-143.
30. Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983;221:1285-1288.
31. Wirths S, Lanzavecchia A. ABCB1 transporter discriminates human resting naive B cells from cycling transitional and memory B cells. Eur J Immunol 2005;35:3433-3441.
32. Dalton WS, Grogan TM, Rybski JA, et al. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood 1989;73:747-752.
33. Sharom FJ, Yu X, Lu P, et al. Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells. Biochem Pharmacol 1999;58:571-586.
34. Chesi M, Nardini E, Lim RS, et al. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998;92:3025-3034.
35. Kalff A, Spencer A. The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. Blood Cancer J 2012;2:e89.
36. Shaughnessy JD Jr., Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007;109:2276-2284.
37. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood 2006;108:2020-2028.
38. Hose D, Reme T, Hielscher T, et al. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica 2011;96:87-95.
39. Agnelli L, Forcato M, Ferrari F, et al. The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma. Clin Cancer Res 2011;17:7402-7412.
40. Hose D, Moreaux J, Meissner T, et al. Induction of angiogenesis by normal and malignant plasma cells. Blood 2009;114:128-143.
41. Martin SK, Diamond P, Williams SA, et al. Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica 2010;95:776-784.
42. Wang YD, De Vos J, Jourdan M, et al. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells. Oncogene 2002;21:2584-2592.
43. Mahtouk K, Jourdan M, De Vos J, et al. An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis. Blood 2004;103:1829-1837.
44. Ongusaha PP, Kwak JC, Zwible AJ, et al. HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer Res 2004;64:5283-5290.
45. Colla S, Tagliaferri S, Morandi F, et al. The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis. Blood 2007;110:4464-4475.
46. Comerford KM, Wallace TJ, Karhausen J, et al. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002;62:3387-3394.
47. Azab AK, Hu J, Quang P, et al. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood 2012;119:5782-5794.
48. Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012;120:1067-1076.
49. Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003;34:267-273.
50. Dalton WS, Grogan TM, Meltzer PS, et al. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989;7:415-424.
51. Epstein J, Xiao HQ, Oba BK. P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. Blood 1989;74:913-917.
52. Salmon SE, Grogan TM, Miller T, et al. Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. J Natl Cancer Inst 1989;81:696-701.
53. Salmon SE, Dalton WS, Grogan TM, et al. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991;78:44-50.
54. Grogan TM, Spier CM, Salmon SE, et al. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993;81:490-495.
55. Hofmeister CC, Yang X, Pichiorri F, et al. Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: Evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. J Clin Oncol 2011;29:3427-3434.
56. Takahashi N, Miura M, Kameoka Y, et al. Drug interaction between lenalidomide and itraconazole. Am J Hematol 2012;87:338-339.
57. Futscher BW, Blake LL, Gerlach JH, et al. Quantitative polymerase chain reaction analysis of mdr1 mRNA in multiple myeloma cell lines and clinical specimens. Anal Biochem 1993;213:414-421.
58. Cripe LD, Uno H, Paietta EM, et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: A randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood 2010;116:4077-4085.
59. Martin SK, Diamond P, Gronthos S, et al. The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia 2011;25:1533-1542.
60. Treins C, Murdaca J, Van Obberghen E, et al. AMPK activation inhibits the expression of HIF-1α induced by insulin and IGF-1. Biochem Biophys Res Commun 2006;342:1197-1202.
61. Mabjeesh NJ, Escuin D, LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;3:363-375.
62. Doublier S, Belisario DC, Polimeni M, et al. HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast. BMC Cancer 2012;12:4.
63. Barretina J, Caponigro G, Stransky N, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-607.
64. Zhao XQ, Xie JD, Chen XG, et al. Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo and ex vivo. Mol Pharmacol 2012;82:47-58.
65. Onishi H, Kai M, Odate S, et al. Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer. Cancer Sci 2011;102:1144-1150.
66. -/- mice. Cancer Cell 2004;6:229-240.
67. Gutman D, Morales AA, Boise LH. Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma. Leukemia 2009;23:2181-2183.
68. Ao L, Wu Y, Kim D, et al. Development of peptide-based reversing agents for P-glycoprotein-mediated resistance to carfilzomib. Mol Pharm 2012;9:2197-2205.
69. Verbrugge SE, Assaraf YG, Dijkmans BA, et al. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis. J Pharmacol Exp Ther 2012;341:174-182.
70. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012;33:207-214.
71. Peacock CD, Wang Q, Gesell GS, et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci USA 2007;104:4048-4053.
72. Blotta S, Jakubikova J, Calimeri T, et al. Canonical and non canonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood 2012;120:5002-5013.
73. Lin TL, Matsui W. Hedgehog pathway as a drug target: Smoothened inhibitors in development. Onco Targets Ther 2012;5:47-58.
74. Zhang Y, Laterra J, Pomper MG. Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp. Neoplasia 2009;11:96-101.
75. Chauhan D, Li G, Auclair D, et al. Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood 2003;101:3606-3614.
76. Rajkumar SV, Richardson PG, Lacy MQ, et al. Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. Clin Cancer Res 2007;13:6162-6167.
77. Zhou Q, Gustafson D, Nallapareddy S, et al. A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer. Invest New Drugs 2011;29:340-346.
78. Kuiper R, Broyl A, de Knegt Y, et al. A gene expression signature for high-risk multiple myeloma. Leukemia 2012;26:2406-2413.
79. Brennan SK, Wang Q, Tressler R, et al. Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS One 2010;5.
80. Ikegame A, Ozaki S, Tsuji D, et al. Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors. Leukemia 2012;26:2124-2134.